Café

© 2026 Longbridge｜Terms of Service Privacy Policy

VNDA

VNDA

5.2600.77%( +0.040 )

LongbridgeAI

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Unusual Whales

May 27, 2026 at 06:03 AM

On May 27, 2026, Vanda Pharmaceuticals Inc. unveiled that Japan's Ministry of Health, Labour and Welfare (MHLW) had awarded orphan drug designation to imsidolimab, a high-affinity humanized IgG4 monoclonal antibody. Vanda, listed on Nasdaq as VNDA, shared this development.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Vanda Pharma

VNDA.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--